These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23859349)

  • 1. Deferiprone for the treatment of Friedreich's ataxia.
    Pandolfo M; Hausmann L
    J Neurochem; 2013 Aug; 126 Suppl 1():142-6. PubMed ID: 23859349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.
    Lee YK; Lau YM; Ng KM; Lai WH; Ho SL; Tse HF; Siu CW; Ho PW
    Int J Cardiol; 2016 Jan; 203():964-71. PubMed ID: 26625322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
    Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
    Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferiprone targets aconitase: implication for Friedreich's ataxia treatment.
    Goncalves S; Paupe V; Dassa EP; Rustin P
    BMC Neurol; 2008 Jun; 8():20. PubMed ID: 18558000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No changes in heme synthesis in human Friedreich´s ataxia erythroid progenitor cells.
    Steinkellner H; Singh HN; Muckenthaler MU; Goldenberg H; Moganty RR; Scheiber-Mojdehkar B; Sturm B
    Gene; 2017 Jul; 621():5-11. PubMed ID: 28412459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of frataxin in fission yeast iron metabolism: implications for Friedreich's ataxia.
    Wang Y; Wang Y; Marcus S; Busenlehner LS
    Biochim Biophys Acta; 2014 Oct; 1840(10):3022-33. PubMed ID: 24997422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones.
    Shan Y; Napoli E; Cortopassi G
    Hum Mol Genet; 2007 Apr; 16(8):929-41. PubMed ID: 17331979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.
    Velasco-Sánchez D; Aracil A; Montero R; Mas A; Jiménez L; O'Callaghan M; Tondo M; Capdevila A; Blanch J; Artuch R; Pineda M
    Cerebellum; 2011 Mar; 10(1):1-8. PubMed ID: 20865357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches.
    Schmucker S; Puccio H
    Hum Mol Genet; 2010 Apr; 19(R1):R103-10. PubMed ID: 20413654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia.
    Chiang S; Kovacevic Z; Sahni S; Lane DJ; Merlot AM; Kalinowski DS; Huang ML; Richardson DR
    Clin Sci (Lond); 2016 Jun; 130(11):853-70. PubMed ID: 27129098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia.
    Alfedi G; Luffarelli R; Condò I; Pedini G; Mannucci L; Massaro DS; Benini M; Toschi N; Alaimo G; Panarello L; Pacini L; Fortuni S; Serio D; Malisan F; Testi R; Rufini A
    Mov Disord; 2019 Mar; 34(3):323-334. PubMed ID: 30624801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aberrant genetic and epigenetic events in Friedreich's ataxia.
    Quesada MP; Jones J; Rodríguez-Lozano FJ; Moraleda JM; Martinez S
    Exp Cell Res; 2015 Jul; 335(1):51-61. PubMed ID: 25929520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.
    Elincx-Benizri S; Glik A; Merkel D; Arad M; Freimark D; Kozlova E; Cabantchik I; Hassin-Baer S
    J Child Neurol; 2016 Jul; 31(8):1036-40. PubMed ID: 27029487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial pathophysiology in Friedreich's ataxia.
    González-Cabo P; Palau F
    J Neurochem; 2013 Aug; 126 Suppl 1():53-64. PubMed ID: 23859341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia.
    Auchère F; Santos R; Planamente S; Lesuisse E; Camadro JM
    Hum Mol Genet; 2008 Sep; 17(18):2790-802. PubMed ID: 18562474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Friedreich's ataxia: past, present and future.
    Marmolino D
    Brain Res Rev; 2011 Jun; 67(1-2):311-30. PubMed ID: 21550666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia.
    Anzovino A; Lane DJ; Huang ML; Richardson DR
    Br J Pharmacol; 2014 Apr; 171(8):2174-90. PubMed ID: 24138602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
    Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
    Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron dysregulation in Friedreich ataxia.
    Wilson RB
    Semin Pediatr Neurol; 2006 Sep; 13(3):166-75. PubMed ID: 17101455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in the Treatment Strategies of Friedreich's Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms.
    Saini AK; Anil N; Vijay AN; Mangla B; Javed S; Kumar P; Ahsan W
    Curr Pharm Des; 2024; 30(19):1472-1489. PubMed ID: 38638052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.